CROMSOURCE Trains Italian Physicians on Clinical Research Best Practice
CROMSOURCE is delivering several modules of a training course on clinical research best practice organized by the SIFC (Italian Cystic Fibrosis Society).
CROMSOURCE, an international provider of outsourced services to the pharmaceutical, biotechnology and medical device industries, is delivering several modules of a training course on clinical research best practice organized by the SIFC (Italian Cystic Fibrosis Society). The course commenced in December 2014 and will complete in February 2015.
Effective development of therapies in rare diseases such as cystic fibrosis relies on the involvement of physicians working in specialized clinics. These clinicians are then able to offer participation in such research projects to patients under their care. By offering training in clinical research best practice, SIFC hopes that physicians and their teams may be able to engage even more in future clinical research programs and offer participation to more patients with cystic fibrosis. During the course, CROMSOURCE personnel are training physicians and their teams on topics including typical aspects of a clinical research study protocol, the responsibilities of the physician and clinical staff who are involved in clinical research and the regulatory application and approval process for clinical research.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
